^
    Back
    Association details:
    Biomarker:SIRT3 expression
    Cancer:Hormone Receptor Positive Breast Cancer
    Drug:Ibrance (palbociclib) (CDK4/6 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    SABCS 2023
    Title:

    SIRT3 as a new potential predictive biomarker for response to CDK4/6 inhibition in ER+/HER2- metastatic breast cancer patients

    Published date:
    12/02/2023
    Excerpt:
    This study suggested that SIRT3 expression could represent a potential predictive biomarker in HR+ MBC patients treated with Palbociclib.